MedDataX Logo

Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients

NCT00694720 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-05-01

No results posted yet for this study

Summary

The primary objective of this study is to assess the activity on breathing parameters of 4 escalating doses of AVE0657 in comparison to placebo in patients with Cheynes-Stokes Breathing Syndrome.

Conditions

  • Heart Failure
  • Sleep Apnea Syndromes
  • Cheyne-Stokes Respiration

Interventions

DRUG

AVE0657

capsules once a day at bedtime

DRUG

placebo

capsules once a day at bedtime

Sponsors & Collaborators

  • Sanofi

    lead INDUSTRY

Principal Investigators

  • Patrick LEVY, Professor · Hôpital Michallon - Grenoble - France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • France
  • Germany
  • Spain

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00694720 on ClinicalTrials.gov